Abstract: Leiomyosarcomas (LMSs) constitute approximately one quarter of all sarcomas and are usually defined by morphologic criteria and/or immunoreactivity for actin or desmin. Among high-grade lesions, the distinction from undifferentiated pleomorphic sarcoma (UPS) can be problematic, and previous studies have shown that a significant number of LMS cases may be hiding under the diagnosis of UPS. We recently described 3 novel molecular LMS subtypes that are distributed similarly over LMSs of gyneocologic and non-gyneocologic origins. The group 1 subtype shows an improved disease-specific survival compared with the other 2 groups that is independent of histologic grade. Group 1 comprises approximately 25% of all LMSs, and is defined by a shared pattern of gene expression, a distinct pattern of genomic changes, and reactivity for at least 3 of 5 immunohistochemistry (IHC) markers (smooth muscle gamma actin, calsequestrin 2, human muscle cofilin2, myosin light chain kinase, and sarcolemmal membrane associated protein), as tested on 271 cases of LMS in tissue microarrays. These IHC markers have not been well characterized in non-LMS sarcomas. Here we provide a characterization of these 5 markers across normal tissues, an additional 59 cases of LMS, and a wide range of 565 non-LMS soft tissue tumors from 44 diagnostic categories, with a focus on UPS. When analyzed individually, the 5 markers were found to be expressed in many sarcomas other than LMSs. However, when analyzed by the same criteria used for the recognition of group 1 LMSs, in which a case is scored positive when at least 3 of 5 markers reacted, coordinate expression was seen in significant numbers of cases from only 3 diagnostic groups that included 22% of leiomyomas (n = 22), 16% of gastrointestinal stromal tumors (n = 43), and 18% of endometrial stromal sarcomas (n = 11). In addition, 5% (n = 57) of UPSs showed a staining pattern similar to that seen in group 1 LMSs. To further examine the possibility that group 1 LMS constitutes a small part of cases diagnosed as UPS, we examined the expression of the top 500 genes from the group 1 LMS expression signature in 29 UPSs by complementary DNA microarray. Unsupervised hierarchical clustering of 29 UPS expression showed that 2 (7%) had coordinated high levels of expression of genes from the group 1 LMS signature, a rate similar to that seen by IHC analysis. These findings show that group 1 LMS IHC markers smooth muscle gamma actin, calsequestrin 2, human muscle cofilin2, myosin light chain kinase, and sarcolemmal membrane associated protein when coordinately expressed have specificity for a subset of LMS when compared with other sarcomas, and may be useful for the recognition of group 1 LMS cases within cases diagnosed as UPS.
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Here we report the first large-scale characterization of these 5 LMS group 1 markers across a wide range of benign soft tissue tumors and sarcomas, with a focus on UPS. The IHC staining results for 57 UPSs were compared with previously unpublished GEPs of 29 UPSs to confirm the IHC analyses.
METHODS
IHC staining with ACTG2 (1:2000, cat# H00000072-A01; Novus Biologicals, Littleton, CO), CASQ2 (1:100, cat # GTX90833; GeneTex Inc, Irvine, CA), CFL2 (1:100, cat# GTX92818; Genetic Inc, Irvine, CA), MYLK (1:25, cat# GTX91044; GeneTex Inc, Irvine, CA), and SLMAP (1:2500, cat# GTX94163; GeneTex Inc, Irvine, CA) was performed on tissue arrays TA-167 and TA-170 with 565 cores including sarcomas and benign soft tissue lesions from 44 diagnostic entities and normal tissues. Immunoreactivity was visualized using Vector's Vectastain Elite ABC kit (mouse) after citrate pretreatment for each antibody. The 5 antibodies were chosen because they detect gene products that were among those defining the group 1 subtype by GEP and because commercially available antibodies already existed. 1 The cases on the TMAs were derived from the internal files of the Stanford University Department of Surgical Pathology and were collected using HIPAA compliant Stanford University Medical Center institutional review board approval. All diagnoses were made according to routine practices by department faculty. According to departmental practice, a diagnosis of UPS requires an absence of discernable lineage commitment (including smooth muscle differentiation) by morphology or IHC. All 5 stains were additionally applied to an LMS TMA, TA-201, containing 377 LMSs. We have previously reported IHC findings for TA-201 1 ; these stains were reviewed and verified for this study.
Staining was scored as positive (tumor cell cytoplasmic staining visible by low power), weak/absent, or uninterpretable. Only cores for which >3 of the 5 antibody stains were interpretable were included in the analysis, and only those with Z3 positive markers were considered to show a significant correlation with group 1 LMSs. Digital images from all TMA cores stained by IHC used in this study are publically accessible on the website: http://tma.stanford.edu/.
For GEP studies, the expression of the top 500 genes from the group 1 LMS expression signature 1 was evaluated in 29 cases of UPS on the same 44,000 spot complementary DNA microarray platform used to define the group 1 LMS cases. The 29 UPS cases used for gene expression analysis were centrally reviewed (CF). The cases were clustered together with the 51 LMS cases used in our previous study using expression for these 500 genes by hierarchical clustering.
RESULTS

Staining in Normal Tissues
The group 1 LMS GEP was characterized by an abundance of genes that are known to be involved in muscle differentiation. As expected, the antibodies selected from these gene lists showed reactivity with muscle cells in a variety of sites. However, the reactivity patterns were not uniform and showed significant variability depending on the site of origin of the muscle samples (Fig. 1) .
ACTG2, CFL2, MYLK, and SLMAP diffusely stained smooth muscle cell cytoplasm in the gastrointestinal tract, whereas ACTG2, CFL2, and SLMAP were positive in the myometrium. Only ACTG2 and SLMAP were positive in smooth muscle from the bladder wall. ACTG2 and SLMAP were strongly positive in arterial and venous blood vessels from a variety of sites, whereas CASQ2 showed variable reactivity within vessel walls.
Group 1 markers also stained other muscle subtypes. Cardiac muscle was positive for SLMAP, CFL2, ACTG2, and CASQ2. Interestingly, ACTG2 and CASQ2 showed a more focal and punctate pattern of cytoplasmic reactivity in cardiac muscle when compared with the diffuse cytoplasmic reactivity of these markers in other positive tissues and also when compared with the SLMAP and CFL2 staining patterns in cardiac muscle. Skeletal muscle reacted strongly with ACTG2, CASQ2, and SLMAP, but showed variable staining with MYLK.
No staining for any of the 5 markers was appreciated in hematolymphoid tissue from the tonsil or in a variety of epithelial tissues including the lung, thyroid, salivary gland, bowel mucosa, and kidney.
Staining in Leiomyosarcoma
As reported previously, IHC staining showed immunopositivity for at least 3 of the 5 group 1 markers in 25% (84 of 330) of LMSs (Fig. 2) . A much larger proportion of LMS tumors showed sporadic staining with 1 or 2 of the 5 markers (63%, 209 of 330). It should be noted that the proportion of tumors expressing at least 3 group 1 markers was comparable for LMS of gyneocologic (GYN) (26%, 27 of 105) and non-GYN origins (25%, 57 of 225). Group 1 marker staining patterns were previously described for 271 LMS cases, 1 and staining for an additional 59 cases was included to reach a total of 330 LMS cases. The rationale for choosing a cutoff of at least 3 markers was derived primarily from GEP data, which identified the group 1 tumor subset based on coordinate expression of 360 genes. Although many tumors expressed individual group 1 genes by IHC, the concomitant expression of all 5 genes seemed to be relatively specific to a subset of LMS. 1 As data for all 5 stains were not uniformly available for all cases due to technical difficulties (eg, loss of cores, uninterpretable staining), a minimum requirement of 3 positive stains was chosen to maximize available data while still excluding cases of spurious staining. Using these criteria, the IHC studies identified a subset of LMS cases that represented a similar percentage of cases as identified through GEP.
Staining in Other Soft Tissue Tumor Types
Group 1 marker expression was evaluated in a variety of other sarcomas and benign soft tissue processes (Table 1 ). The majority of lesions did not show coordinate expression of at least 3 markers, and only 3 diagnostic groups showed staining in significant numbers of cases. These included 22% (5 of 22) of benign leiomyomas occurring in GYN (n = 2/19) and non-GYN sites (n = 3/3). In addition, 16% of gastrointestinal stromal tumors (GISTs) (n = 7/43) and 18% of endometrial stromal sarcomas (ESSs) (n = 2/11) reacted with at least 3 group 1 markers. The other sarcomas and benign mesenchymal processes failed to show positive staining with Z3 group 1 markers (Table 1) . Although negative for the group 1 markers as a panel, in some instances non-LMS sarcoma subtypes expressed a single group 1 LMS marker. Notably, single marker expression was present in 38% of liposarcomas (n = 26) and in 13% of rhabdomyosarcomas (n = 15). In these instances, the identity of the positive marker varied across tumor types; however, trends emerged within certain tumor subtypes. For instance, 27% (7 of 26) of liposarcomas were positive for CFL2 but all were negative for SLMAP. 
Staining and Gene Array Data in Undifferentiated Pleomorphic Sarcoma
Expression of Z3 group 1 markers was seen in 5% of UPSs (n = 3/57). These cases were reviewed and were confirmed to be negative for the smooth muscle markers desmin (3 of 3) and smooth muscle actin (2 of 3). A much larger proportion (37%, 21 of 57) of cases showed positivity for at least 1 group 1 marker, similar to the relatively high incidence of staining with a single marker seen in other non-LMS sarcomas. Even in UPS cases in which all 5 markers were positive, staining intensity was diminished when compared with the most convincingly stained LMS cases and normal tissues (Fig. 3) . In addition, although widespread marker positivity was not detected in a variety of other non-LMS sarcomas (with the exception of ESS and GIST, for which there is some biological basis for smooth muscle differentiation and marker reactivity), the study included more UPSs than any other individual sarcoma subtype. Therefore, cases of incidental or specious reactivity would more likely occur in this category.
To further address the reactivity of LMS group 1 in a subset of UPS, GEP was performed. Hierarchical clustering and principal component analysis were carried out on a set of 29 UPSs and 51 previously characterized group 1 and nongroup 1 LMSs 1 using the 500 genes that were used to identify group 1 LMSs in our previous study. The average expression of 500 group 1 genes was calculated, and cases were then ranked according to this value. A cutpoint was determined according to the average gene expression value at which the first nongroup 1 LMS case appeared on the rank list. Using this stringent cutpoint, only rare cases (7%, 2 of 29) of UPS met criteria for positive group 1 gene expression. If a much more permissive cutpoint was used (eg, the average gene expression value of the last group 1 LMS case), 55% (16 of 29) of UPSs qualified for inclusion. 
DISCUSSION
LMS is a malignancy with an aggressive course and limited treatment options. At present, prognosis of LMS is predicted using traditional clinicopathologic features, 15 and the current chemotherapeutic armamentarium for these tumors, is based predominantly on doxorubicin and related therapies and results in only marginal improvements in survival. Although molecular biomarkers do not yet inform prognostication and treatment of LMS in the clinical setting, 13, 14 gene expression microarrays have already been used to detect signatures of probable metastasis in these tumors. 10, 18 In addition, macrophage infiltration 18 and the colony stimulating factor 1 response signature 7 have been identified by our group as poor prognostic factors in LMS. An improved understanding of LMS molecular subtypes could help in forcasting tumor behavior. Given the improved prognosis of group 1 LMS when compared with other LMS subtypes, reliable distinction of group 1 from both other LMS subtypes and other soft tissue sarcomas is critical. Our studies here are intended to determine whether 5 IHC markers shown previously to be useful for the distinction of group I LMS (with good prognosis) could be useful in a clinical setting. Our findings suggest that the novel markers ACTG2, CASQ2, CFL2, MYLK, and SLMAP are valuable tools in the diagnosis of group 1 LMS, a subset of LMS cases that we previously defined by GEP. 1 The presence of strong group 1 marker expression in 25% of LMSs in this study coincides with previously reported finding that group 1 comprises approximately 25% of LMS.
1 When used in concert, these markers were also useful in distinguishing group 1 LMSs from a variety of other sarcomas. Individually, however, the antibody stains had variable reactivity profiles and did not infrequently stain other non-LMS sarcomas. These findings suggest that a panel of stains is a powerful tool for the diagnosis of group 1 LMS, whereas single markers are only of limited use depending on the differential diagnosis.
One frequently encountered diagnostic problem for which individual markers may be of value is in the distinction of LMS from dedifferentiated liposarcoma. Although diagnosis is straightforward in morphologically classic cases, differentiating LMS from liposarcoma may be difficult when the former entraps significant amounts of fat or the latter shows areas of divert differentiation. 4 Expression of SLMAP was highly specific (100%) for LMS when the differential was limited to LMS versus liposarcoma. MYLK performed similarly showed 96% specificity for LMS when applied in this focused differential.
The presence of strong group 1 marker expression in significant numbers of ESS and GIST is intriguing. Smooth muscle differentiation is well documented in both tumors. In the case of ESS, admixed areas of benign smooth muscle are relatively common and are not thought to influence prognosis so long as cytologic atypia is absent. The presence of any significant atypia in areas of smooth muscle differentiation excludes the diagnosis of ESS and places the lesion under consideration for a diagnosis of LMS. 20 Group 1 marker staining in bland smooth muscle components of ESS is not surprising, given that a subset of benign smooth muscle tumors react with these immunostains, and should not represent a source of additional diagnostic difficulty in the distinction of ESS and LMS.
Group 1 marker staining was also noted in some GISTs. A subset of these GISTs has been shown to demonstrate histologic features of smooth muscle differentiation with desmin and actin positivity. Initial study suggested distinct differences in gene copy number between LMS and GIST, 19 whereas recent molecular studies have shown common regions of 13q and 11q imbalance in GIST and LMS. 23 Further study is warranted to evaluate the significance of the morphologic, IHC, and molecular overlap of some GISTs with LMS.
Although the group 1 subtype includes a greater proportion of histologically well-differentiated LMSs than the other LMS clusters, the prognostic significance of group 1 is independent of grade.
1 Moreover, the absence of strong group 1 staining in the majority of leiomyomas provides argument against the supposition that the group 1 subtype constitutes a better differentiated form of LMS. In addition, these clinically well-behaving tumors paradoxically show increased levels of genomic complexity, with shared affected genes, when compared with other LMSs. 1, 2, 17 An earlier study has also shown that the most frequently lost region in group 1 LMS spans 2.5 MB on 1p36.32, which includes the PRDM16 gene. The loss of PRDM16 promotes differentiation of brown fat precursors into the skeletal muscle and results in elevated expression of genes involved in smooth, cardiac, and skeletal muscles (including ACTG2, MYLK, CFL2, SLMAP, and CASQ2). 1, 21 The heterogeneity of muscle genes expressed in group 1 tumors may help to explain the frequent overlap of individual group 1 immunostains with other sarcoma subtypes.
Despite the increased genetic complexity of group 1 LMS, patients with these tumors experience a survival benefit that is independent of histologic grade 1 suggesting that factors beyond the degree of differentiation influence prognosis. The finding that the group 1 phenotype connotes improved prognosis irrespective of differentiation is of particular interest in cases of UPS showing strong group 1 marker expression by IHC, particularly given the finding that a comparable percentage of UPS shows high coordinated group 1 gene expression on hierarchical clustering of complementary DNA microarrays. These markers may define a small population of group 1 LMSderived UPS with improved prognosis and could suggest future therapeutic targets. This is especially relevant given that myogenic differentiation usually confers worse prognosis with increased risk of metastasis and decreased overall survival in UPS. 6, 8 Although the rarity of group 1 marker-positive UPS argues against the possibility that large numbers of group 1 LMS hide within the UPS category, reappraisal of UPS with group 1 features may provide prognostically useful information.
